Share on LinkedInShare on LinkedIn

ARTICLE · 23 SEPTEMBER 2026

Parties Dispute Intent Standard In STELARA® Antitrust Appeal

CareFirst's antitrust appeal against Johnson & Johnson over STELARA® patent acquisition reaches the Fourth Circuit, with parties disputing whether monopolization requires specific intent to exclude competitors. The Federal Trade Commission has weighed in with an amicus brief challenging the district court's interpretation of antitrust law standards.

United StatesAntitrust/Competition Law

As we previously reported, portions of CareFirst’s antitrust claims concerning STELARA® (ustekinumab) survived summary judgment in December 2025.

On January 14, 2026, the U.S. District Court for the Eastern District of Virginia reconsidered that decision and granted summary judgment to Johnson & Johnson and Janssen Biotech, Inc. (collectively, “J&J”) on CareFirst’s theory that J&J’s acquisition of four Momenta Pharmaceuticals manufacturing patents violated Section 2 of the Sherman Act. The court found insufficient evidence that, at the time of the acquisition, J&J intended to use the patents to exclude competitors. On February 10, 2026, the court directed entry of final judgment for J&J. CareFirst appealed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from